Background: The term "acute coronary syndrome" (ACS) refers to a group of cardiovascular disorders characterized by abrupt, decreased blood flow to the heart muscle. The present study was conducted to assess efficacy of Neutrophil Gelatinase Associated Lipocalin as a biomarker for acute kidney injury. Materials & Methods: 80 patients with acute coronary syndrome of both genders underwent a comprehensive history and examination. A sample of urine was taken. A standardized clinical platform was used to measure urine NGAL assays. The baseline, 24-hour, and 48-hour serum creatinine levels were also measured. Results: Out of 80 patients, males were 48 and females were 32. The mean serum creatinine level at baseline was 1.09 mg/dl, after 24 hours was 1.20 mg/dl and after 48 hours was 1.56 mg/dl. The difference was significant (P< 0.05). The mean urinary NGAL level was 78.5 in non- AKI and 415.2 in AKI group. The difference was significant (P< 0.05). There was a correlation between Urinary NGAL and AKI. This correlation was statistically significant (P<0.05). Conclusion: In individuals with acute coronary syndrome, urine Neutrophil Gelatinase Associated Lipocalin has demonstrated potential as a biomarker for acute kidney injury (AKI).